ERBB2 and breast carcinoma: As opposed to surgical resection and adjuvant chemotherapy, most patients with triple-negative and HER2-positive breast cancer now undergo systemic neoadjuvant chemotherapy as a standard of care, showing high pathological response and positive long-term outcome [2,3].